IP Verse

Compositions And Methods Of Treating Pulmonary Hypertension - EP2637664

The patent EP2637664 was granted to Gilead Sciences on Mar 29, 2017. The application was originally filed on Oct 14, 2011 under application number EP11833507A. The patent is currently recorded with a legal status of "Revoked".

EP2637664

GILEAD SCIENCES
Application Number
EP11833507A
Filing Date
Oct 14, 2011
Status
Revoked
Feb 22, 2019
Grant Date
Mar 29, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (6)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SANDOZDec 22, 2017PRUFER & PARTNER MBB PATENTANWALTE RECHTSANWALTEADMISSIBLE
GENERICS UKDec 21, 2017TER MEER STEINMEISTER & PARTNERADMISSIBLE
TEVA PHARMACEUTICALSDec 21, 2017BESTADMISSIBLE
ZENTIVA GROUPDec 21, 2017TER MEER STEINMEISTER & PARTNERADMISSIBLE
ALFRED E TIEFENBACHERDec 20, 2017HAMM & WITTKOPPADMISSIBLE
STADA ARZNEIMITTELDec 20, 2017HAMM & WITTKOPPADMISSIBLE

Patent Citations (7) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTUS2006205733
INTERNATIONAL-SEARCH-REPORTUS2008139593
INTERNATIONAL-SEARCH-REPORTWO2008073927
OPPOSITIONWO2006026395
OPPOSITIONWO2008073928
OPPOSITIONWO2012051559
OTHERWO2012051559

Non-Patent Literature (NPL) Citations (24) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- "Ambrisentan gegen Lungenhochdruck", Deutsche Apotheker Zeitung, (20080000), pages 1 - 5, XP055450995-
OPPOSITION- B. CASSERLY et al., "Ambrisentan for the treatment of pulmonary arterial hypertension", Drug Design, Development and Therapy, (20080000), vol. 2, pages 265 - 280, XP055451011-
OPPOSITION- Clinical Trials gov, "A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis", clinicaltrials.gov,, (20100104), URL: https://clinicaltrials.gov/archive/NCT01042158/2010_01_04, XP002762841-
OPPOSITION- Clinical Trials Gov, "A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)", clinicaltrials.gov,, (20101001), URL: https://clinicaltrials.gov/archive/NCT01178073/2010_10_01, XP055451989-
OPPOSITION- Clinical Trials Gov, "A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects with Pul- monary Arterial Hypertension (PAH)", ClinicalTrials.gov archive, (20100806), URL: https://clinicaltrials.gov/archive/NCT01178073/2010_08_06, XP055451937-
OPPOSITION- Clinical Trials Gov, "A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects with Pulmonary Arterial Hypertension (PAH)", ClinicalTrials.gov archive, (20100806), URL: https://clinicaltrials.gov/archive/NCT01178073/2010_08_06, XP055451937-
OPPOSITION- Clinical Trials gov, "Study of Ambrisentan and Phosphodiesterase Type-5 Inhibitor (PDE-5i) to Treat Pulmonary Arterial Hypertension", clinicaltrials.gov,, (20100622), URL: https://clinicaltrials.gov/archive/NCT00617305/2010_06_22, XP055451984-
OPPOSITION- "First-Line Combination of Ambrisentan and Tadalafil Reduces Risk of Clinical Failure Compared to Monotherapy in Pulmonary Arterial Hypertension Outcomes Study", ERS International Congress, (20140908), pages 1 - 4, XP055143841-
OPPOSITION- Gilead Sciences, "Gilead Sciences Announces Plans for Phase IV Clinical Trial Evaluating First-Line Combination Therapy Versus Monotherapy in Pulmonary Ar- terial Hypertension", (20091102), URL: http://phx.corporate-ir.net/External.File?t=2&item=g7rqBLVLuv81UAmrh20Mp4eJK6Hn0WwjUbilyOR+y5+htLdlD91L0XHJHVC8KDIVtJJd3DvcFh7A+dhAxGuRwA==, XP002762840-
OPPOSITION- Gilead Sciences, "Gilead Sciences Announces Plans for Phase IV Clinical Trial Evaluating First-Line Combination Therapy Versus Monotherapy in Pulmonary Arterial Hypertension", (20091102), URL: http://phx.corporate-ir.net/External.File?t=2&item=g7rqBLVLuv81UAmrh20Mp4eJK6Hn0WwjUbilyOR+y5+htLdlD91L0XHJHVC8KDIVtJJd3DvcFh7A+dhAxGuRwA==, XP002762840-
OPPOSITION- Gilead Sciences, "Study of combination therapy versus monotherapy for pulmonary arterial hypertension", (20091102), URL: https://www.news-medical.net/news/20091102/Study-of-combination-therapy-versus-monotherapy-for-pulmonary-arterial-hypertension.aspx, XP055451949-
OPPOSITION- IHEAGWARA et al., "Pharmacologic Treatment of Pulmonary Hypertension", Practica Farmaceutica, (20100000), vol. 2, no. 1-2, pages 50 - 56, XP055122243-
OPPOSITION- IHEAGWARA et al., "Pharmacologic Treatment of Pulmonary Hypertension", Practica Farmaceutica, (20100000), vol. 3, no. 1-2, XP055122243-
OPPOSITION- LIANG, F. et al., "Ambrisentan and Tadalafil Synergistically Relax Endothelin-Induced Contraction of Rat Pulmonary Arteries /Abstract/", American Thoracic Society 2011 International Conference, (20110517), XP055451974-
OPPOSITION- "Neue Arzneimittel Adcirca@ (Tadalafil)", Information der Arzneimittelkommission, (20100616), pages 1 - 2, XP055450999-
OPPOSITION- SANDY WALSH, "FDA approves new orphan drug for treatment of pulmonary arterial hypertension", FDA News, (20070615), URL: http://web.archive.org/web/20070623055608/http://www.fda.gov/bbs/topics/NEWS/2007/NEW01653.html, XP002726332-
OPPOSITION- SPENCE et al., "No Clinically Relevant Pharmacokinetic and Safety Interactions of Ambrisentan in Combination With Tadalafil in Healthy Volunteers", Journal of Pharmaceutical Sciences, (20091200), vol. 98, no. 12, pages 4962 - 4974, XP002726333
OPPOSITION- SPENCE et al., "No Clinically Relevant Pharmacokinetic and Safety Interactions of Ambrisentan in Combination With Tadalafil in Healthy Volunteer s", Journal of Pharmaceutical Sciences, (20091201), vol. 98, no. 12, pages 4962 - 4974, XP002726333
OPPOSITION- SPENCE et al., "No Clinically Relevant Pharmacokinetic and Safety Interactions of Ambrisentan in Combination With Tadalafil in Healthy Volunteers", J. Pharm. Sci., (20090000), vol. 98, no. 12, pages 4962 - 4974, XP002726333
OPPOSITION- L.J. RUBIN, "Ambrisentan for pulmonary arterial hypertension", Future Cardiol., (20050000), vol. 1, no. 4, pages 425 - 432, XP009128401
SEARCH- Sandy Walsh, "FDA Approves New Orphan Drug for Treatment of Pulmonary Arterial Hypertension", (20070615), FDA News, URL: http://web.archive.org/web/20070623055608/http://www.fda.gov/bbs/topics/NEWS/2007/NEW01653.html, (20140626), XP002726332 [Y] 1-11 * the whole document *-
SEARCH- SPENCE REBECCA ET AL, "No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers.", JOURNAL OF PHARMACEUTICAL SCIENCES DEC 2009, (200912), vol. 98, no. 12, ISSN 1520-6017, pages 4962 - 4974, XP002726333 [I] 1-11 * the whole document * [Y] 1-11
SEARCH- MCLAUGHLIN V ET AL, "Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis.", RHEUMATOLOGY (OXFORD, ENGLAND) JUN 2009, (200906), vol. 48 Suppl 3, ISSN 1462-0332, pages iii25 - iii31, XP002726334 [Y] 1-11 * the whole document *
SEARCH- N. GALIE ET AL, "Tadalafil Therapy for Pulmonary Arterial Hypertension", CIRCULATION, (20090526), vol. 119, no. 22, doi:10.1161/CIRCULATIONAHA.108.839274, ISSN 0009-7322, pages 2894 - 2903, XP055125592 [Y] 1-11 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents